The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors

Table 1

Baseline characteristics of the study population.

	Overall	RDCI=0	RDCI=1	RDCI=2	RDCI≥3	P
	n = 346	n = 204	n = 71	n = 46	n = 25
Mean age ± SD, years	53.45 ± 13.03	51.59±13.59	53.49±12.2	57.56±11.33	60.91±9.2	0.001
Female, n (%)	282 (81.5)	169 (82.8)	58 (81.7)	38 (82.6)	17 (68)	0.347
Mean disease duration ± SD, years	11.48 ± 9.13	11.37±8.91	11.59±10.92	11.43±8.23	12.15±7.08	0.515
Mean DAS28-ESR ± SD	5.29 ± 1.23	5.27±1.22	5.17±1.33	5.48±1.18	5.40±1.06	0.842
Mean HAQ score ± SD	1.39 ± 0.56	1.34±0.55	1.38±0.53	1.52±0.60	1.54±0.68	0.134
Positive RF, n (%)	260 (75.1)	151 (74)	51 (71.8)	37 (80.4)	21 (84)	0.514
Concomitant MTX, n (%)	189 (54.6)	114 (55.9)	36 (50.7)	22 (47.8)	17 (68)	0.099
Low-dose, n (%)	112 (33.9)	65 (57.0)	17 (47.2)	17 (77.3)	13 (76.5)
High-dose, n (%)	77 (23.4)	49 (43.0)	19 (52.8)	5 (22.7)	4 (23.5)
bDMARD, n (%)						0.306
Etanercept	174 (50.3)	108 (53.6)	31 (43.6)	20 (43.4)	15 (60.0)
Adalimumab	172 (49.7)	96 (46.4)	40 (56.4)	26 (56.6)	10 (40.0)

bDMARD: Biologic Disease Modifying Antirheumatic Drugs; DAS28-ESR: Disease Activity Score 28-Erythrocyte Sedimentation Rate; HAQ: Health Assessment Questionnaire; MTX: Methotrexate; RDCI: Rheumatic Disease Comorbidity Index; RF: Rheumatoid Factor; SD: Standard Deviation. Kruskal-Wallis test; chi-squared test.